Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Indications/Uses

Mantle Cell Lymphoma (MCL): CALQUENCE as monotherapy is indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
CALQUENCE in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant (ASCT).
Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL): CALQUENCE is indicated: in combination with obinutuzumab or as monotherapy for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
In combination with venetoclax with or without obinutuzumab for the treatment of patients with previously untreated CLL/SLL.
As monotherapy for the treatment of patients with CLL/SLL who have received at least one prior therapy.

Calquence Indications/Uses

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma